Richard Tobin cited positive margin mix from growth platforms for BioPharma.
1 report, 1 independent
Updated Jul 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Richard Tobin cited positive margin mix from growth platforms for BioPharma.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.Also in this story
- Agilent is discussing revenue growth due to stable demand and biopharma recovery, while also noting how tariff concerns are impacting order trends in China.
- Slowdown in pharmaceutical spending in China is impacting companies like Novartis, with potential effects from US generic market entries.
- Harvard Bioscience is facing revenue decline due to macro uncertainty over tariffs and ongoing issues regarding NIH funding.
The entities involved
-
BioPharma
company in Jílové u Prahy, Czech Republic
Coverage
Newest first; wire copies grouped- StockStoryDOV Q2 Deep Dive: Secular Growth Platforms Drive Margins Amid Mixed Industrial Demand Manufacturing company Dover (NYSE:DOV) reported Q2 CY2025 results beating Wall Street’s revenue expectations , wi